journal article·2024-09Open access

Gold Nanoparticle Transport in the Injured Kidneys with Elevated Renal Function Biomarkers

Xuhui Ning, Yuncheng Zhong, Qi Cai, Yaohong Wang, Xun Jia, Jer‐Tsong Hsieh, Jie Zheng, Mengxiao Yu

Advanced Materials· Volume 36· Issue 36

Abstract

Abstract Renal function biomarkers such as serum blood urea nitrogen (BUN) and creatinine (Cr) serve as key indicators for guiding clinical decisions before administering kidney‐excreted small‐molecule agents. With engineered nanoparticles increasingly designed to be renally clearable to expedite their clinical translation, understanding the relationship between renal function biomarkers and nanoparticle transport in diseased kidneys becomes crucial to their biosafety in future clinical applications. In this study, renal‐clearable gold nanoparticles (AuNPs) are used as X‐ray contrast agents to noninvasively track their transport and retention in cisplatin‐injured kidneys with varying BUN and Cr levels. The findings reveal that AuNP transport is significantly slowed in the medulla of severely injured kidneys, with BUN and Cr levels elevated to 10 times normal. In mildly injured kidneys, where BUN and Cr levels only four to five times higher than normal, AuNP transport and retention are not predictable by BUN and Cr levels but correlate strongly with the degree of tubular injury due to the formation of gold–protein casts in the Henle's loop of the medulla. These results underscore the need for caution when employing renal‐clearable nanomedicines in compromised kidneys and highlight the potential of renal‐clearable AuNPs as X‐ray probes for assessing kidney injuries noninvasively.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Heavy Metal Exposure and Toxicity · Acute Kidney Injury Research · Trace Elements in Health

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Biochemistry The University of Texas at Dallas Richardson TX 75080 USA

Department of Radiation Oncology The University of Texas Southwestern Medical Center Dallas TX 75235 USA

Department of Pathology The University of Texas Southwestern Medical Center Dallas TX 75390 USA

Department of Pathology Microbiology, and Immunology Vanderbilt University Medical Center Nashville TN 37232 USA

Department of Urology The University of Texas Southwestern Medical Center Dallas TX 75390 USA

Funding

National Institutes of Health · Cancer Prevention and Research Institute of Texas

References (82)

Show source-provided references
1. 10.1016/j.kisu.2021.11.00310.1016/j.kisu.2021.11.003 ↗
2. 10.1016/j.kint.2019.07.01210.1016/j.kint.2019.07.012 ↗
3. 10.1016/S0140-6736(20)30925-910.1016/S0140-6736(20)30925-9 ↗
4. 10.1038/s41581-019-0247-z10.1038/s41581-019-0247-z ↗
5. Jones G. R. · Clin. Biochem. Rev. · 2011 · 32 · 81
6. 10.1002/wnan.119810.1002/wnan.1198 ↗
7. 10.1038/ncpneph066010.1038/ncpneph0660 ↗
8. 10.1038/s41568-020-00308-y10.1038/s41568-020-00308-y ↗
9. 10.1038/s41581-022-00631-710.1038/s41581-022-00631-7 ↗
10. 10.1002/cpt.72610.1002/cpt.726 ↗
11. 10.1177/205435811877857310.1177/2054358118778573 ↗
12. 10.1007/s11096-013-9912-710.1007/s11096-013-9912-7 ↗
13. 10.1038/nbt134010.1038/nbt1340 ↗
14. 10.1038/s41578-018-0038-310.1038/s41578-018-0038-3 ↗
15. 10.1038/s41581-024-00819-z10.1038/s41581-024-00819-z ↗
16. 10.1021/acsnano.5b0132010.1021/acsnano.5b01320 ↗
17. 10.1021/ja401612x10.1021/ja401612x ↗
18. 10.1126/scitranslmed.300952410.1126/scitranslmed.3009524 ↗
19. 10.1007/978-1-4939-2326-7_1310.1007/978-1-4939-2326-7_13 ↗
20. 10.1016/j.radonc.2021.04.02110.1016/j.radonc.2021.04.021 ↗
21. 10.1002/adma.20140296410.1002/adma.201402964 ↗
22. 10.1007/s12274-017-1472-z10.1007/s12274-017-1472-z ↗
23. 10.1002/anie.20201018710.1002/anie.202010187 ↗
24. 10.1002/anie.20150786810.1002/anie.201507868 ↗
25. 10.1002/anie.20151114810.1002/anie.201511148 ↗
26. 10.1002/anie.20170781910.1002/anie.201707819 ↗
27. 10.1002/anie.20190152510.1002/anie.201901525 ↗
28. 10.1038/s41578-021-00328-610.1038/s41578-021-00328-6 ↗
29. 10.1002/anie.20211427310.1002/anie.202114273 ↗
30. 10.1021/bk-2023-1457.ch01510.1021/bk-2023-1457.ch015 ↗
31. 10.1002/anie.20201727310.1002/anie.202017273 ↗
32. 10.1002/anie.20190956010.1002/anie.201909560 ↗
33. 10.1002/adma.20190853010.1002/adma.201908530 ↗
34. J.Zheng M.Yu X.Ning US Provisional Patent Application No. 62/810 626 filed on Feb. 2019. US Patent Application Publication Number: US 2022/0146523 A1 2022.
35. 10.1038/s41563-019-0378-410.1038/s41563-019-0378-4 ↗
36. 10.1126/sciadv.abd984710.1126/sciadv.abd9847 ↗
37. 10.1002/anie.20230653910.1002/anie.202306539 ↗
38. 10.1038/s41563-022-01224-210.1038/s41563-022-01224-2 ↗
39. 10.1038/s41565-019-0527-610.1038/s41565-019-0527-6 ↗
40. 10.1038/s41467-020-16544-710.1038/s41467-020-16544-7 ↗
41. 10.1038/s41467-021-21714-210.1038/s41467-021-21714-2 ↗
42. 10.1038/s41467-018-07890-810.1038/s41467-018-07890-8 ↗
43. 10.1002/adma.20230128310.1002/adma.202301283 ↗
44. 10.1002/adma.20231073110.1002/adma.202310731 ↗
45. 10.1038/s41467-019-13143-z10.1038/s41467-019-13143-z ↗
46. 10.1016/j.jconrel.2020.03.02010.1016/j.jconrel.2020.03.020 ↗
47. 10.1002/anie.20190325610.1002/anie.201903256 ↗
48. 10.1002/adma.20190589910.1002/adma.201905899 ↗
49. 10.7150/thno.7280310.7150/thno.72803 ↗
50. 10.1021/acsnano.2c0534210.1021/acsnano.2c05342 ↗
51. 10.1038/s41565-023-01381-810.1038/s41565-023-01381-8 ↗
52. W. W. T.Ma AnthonyW. C. A.Perez D.Orr E.Hamilton Y.Zhao Y. R.Murciano‐Goroff C.Anders G. P.Adams C. W.Reddick H.Wroe‐McClintock E.Bayever https://d1io3yog0oux5.cloudfront.net/_a904fd60d16ca981a93939ef7ac7fbaf/elucidaoncology/files/docs/publications/20231023/Elucida_ESMO_2023_PosterSession_due2023_OCT_12._Rev_2.pdf.
53. 10.1021/jacs.1c0747110.1021/jacs.1c07471 ↗
54. 10.1002/adfm.20200836210.1002/adfm.202008362 ↗
55. 10.1038/nnano.2016.16410.1038/nnano.2016.164 ↗
56. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Drug Products Including Biological Products that Contain Nanomaterials Guidance for Industry https://www.fda.gov/media/157812/download 2022.
57. 10.1002/anie.20180784710.1002/anie.201807847 ↗
58. Hall J. E. · 2016
59. Clapp W. L. · 2017 · 1
60. 10.1038/s41581-022-00539-210.1038/s41581-022-00539-2 ↗
61. 10.3390/toxins211249010.3390/toxins2112490 ↗
62. 10.1038/s41565-023-01366-710.1038/s41565-023-01366-7 ↗
63. 10.1002/anie.20120303110.1002/anie.201203031 ↗
64. 10.1002/anie.20171058410.1002/anie.201710584 ↗
65. 10.1039/c2nr31192e10.1039/c2nr31192e ↗
66. 10.1039/C8DT00420J10.1039/C8DT00420J ↗
67. 10.1021/jp912258410.1021/jp9122584 ↗
68. 10.1021/acsami.7b1176910.1021/acsami.7b11769 ↗
69. Vasimalai N. · 2018
70. 10.1088/0957-4484/27/47/47550510.1088/0957-4484/27/47/475505 ↗
71. 10.1002/anie.20160279510.1002/anie.201602795 ↗
72. 10.1021/ja035473v10.1021/ja035473v ↗
73. 10.1103/PhysRevLett.93.07740210.1103/PhysRevLett.93.077402 ↗
74. 10.1159/00052549110.1159/000525491 ↗
75. Meehan S. · 2017 · 449
76. 10.1046/j.1523-1755.2002.00364.x10.1046/j.1523-1755.2002.00364.x ↗
77. 10.2967/jnumed.122.26445310.2967/jnumed.122.264453 ↗
78. 10.1038/s41598-021-81519-710.1038/s41598-021-81519-7 ↗
79. 10.1073/pnas.240313112110.1073/pnas.2403131121 ↗
80. 10.1038/sj.ki.500278610.1038/sj.ki.5002786 ↗
81. Cohen A. H. · 2006 · 153
82. Zhou H. · Nephrol Self Assess Program · 2006 · 5 · 63